ONM-501 shown to be promising immuno-therapeutic candidate for clinical evaluation in solid tumors SOUTHLAKE, Texas…
Oscar LazcanoNovember 14, 2022
- Interim Phase 2 results presented at World Molecular Imaging Conference 2022 - - Pegsitacianine…
Oscar LazcanoSeptember 29, 2022
SOUTHLAKE, Texas – September 19, 2022 – OncoNano Medicine, Inc., a clinical-stage biotechnology company focused…
James KrahulaSeptember 19, 2022
SOUTHLAKE, Texas – September 14, 2022 – OncoNano Medicine, Inc. today announced a presentation of…
Oscar LazcanoSeptember 14, 2022
- Oncology Development Veteran to Lead the Advancement of OncoNano’s Portfolio SOUTHLAKE, Texas – June…
James KrahulaJune 1, 2022
SOUTHLAKE, Texas – May 10, 2022 – OncoNano Medicine, Inc. today announced the appointment of…
Oscar LazcanoMay 10, 2022
